News

Filter

GlaxoSmithKline/HGS's Benlysta will push SLE drug market to more than $1.6 billion in 2019

10-08-2010

Driven primarily by the launch and uptake of Human Genome Sciences and GlaxoSmithKline's Benlysta (belimumab),…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMabTheraMarkets & MarketingPharmaceuticalRituxan

COMPANY SPOTLIGHT

Menarini

Back to top